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Background. Many studies have reported that cannabis use increases the risk of a ﬁrst episode of psychosis (FEP).
However, only a few studies have investigated the nature of cannabis-related experiences in FEP patients, and none
has examined whether these experiences are similar in FEP and general populations. The aim of this study was to explore
differences in self-reported cannabis experiences between FEP and non-psychotic populations.
Method. A total of 252 subjects, who met International Classiﬁcation of Diseases (ICD)-10 criteria for FEP, and 217 con-
trols who reported cannabis use were selected from the Genetics and Psychosis (GAP) study. The Medical Research
Council Social Schedule and the Cannabis Experience Questionnaire were used to collect sociodemographic data and
cannabis use information, respectively.
Results. Both ‘bad’ and ‘enjoyable’ experiences were more commonly reported by FEP subjects than controls. Principal
components factor analysis identiﬁed four components which explained 62.3% of the variance. Linear regression analysis
on the whole sample showed that the type of cannabis used and beliefs about the effect of cannabis on health all con-
tributed to determining the intensity and frequency of experiences. Linear regression analysis on FEP subjects showed
that the duration of cannabis use and amount of money spent on cannabis were strongly related to the intensity and
frequency of enjoyable experiences in this population.
Conclusions. These results suggest a higher sensitivity to cannabis effects among people who have suffered their ﬁrst
psychotic episode; this hypersensitivity results in them reporting both more ‘bad’ and ‘enjoyable’ experiences. The
greater enjoyment experienced may provide an explanation of why FEP patients are more likely to use cannabis and
to continue to use it despite experiencing an exacerbation of their psychotic symptoms.
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Introduction
Cannabis is the most commonly used illicit drug inter-
nationally (United Nations Ofﬁce on Drugs and Crime,
2014), and there is a current move in a number of coun-
tries to decriminalize or legalize its use. Previous stud-
ies in non-psychotic populations (Kendler & Prescott,
1998; Kendler et al. 2000, 2015) highlight that a
combination of genetic and environmental factors
inﬂuence cannabis use. Patients with psychosis are
more likely to use cannabis than the general popula-
tion (D’Souza, 2007) but psychosis-prone individuals
are not more likely to use cannabis (Henquet et al.
2005). Although cannabis use is widely recognized
both as increasing risk for the development of psych-
osis and for exacerbating the course of psychotic illness
(Henquet et al. 2005; D’Souza, 2007; Giordano et al.
2015), the processes through which cannabis has
these effects remain largely unknown. Several theoret-
ical models have been proposed. The indicator variable
model hypothesizes that there are other factors that
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cause both psychosis proneness and cannabis use
(D’Souza et al. 2009). The self-medication hypothesis
(Khantzian, 1985) posits that the intoxicating effects
of cannabis (and other drugs) relieve both positive
and negative symptoms of psychosis and that, there-
fore, people experiencing psychosis are more likely to
use, and continue to use, cannabis; nevertheless this
has not been supported by empirical studies
(Kolliakou et al. 2015). Lastly, there is the causal
model, which proposes that the risk of developing
psychosis is increased by the use of cannabis. It points
out that even though the majority of cannabis users
will not develop psychotic symptomatology, cannabis
use is associated with an increased risk of later psych-
otic experiences (Henquet et al. 2008; Casadio et al.
2011), while continued cannabis use is associated
with poorer outcomes among individuals with psych-
osis (Zammit et al. 2008; van der Meer et al. 2015).
The causal model has attracted most support in re-
cent years. However, it leaves an important question
unanswered: ‘why do patients with psychosis use or
continue to use the drug if it makes them worse?’
Indeed, the exact reasons why patients with psychosis
use cannabis remain unclear. There has been little em-
pirical research examining whether the subjective
effects of cannabis differ between individuals with
psychosis and members of the general population.
This has been investigated, for the ﬁrst time, in the pre-
sent study. If psychosis is associated with a greater re-
activity to, and enjoyment of, the effects of cannabis
this might help explain the continued use of cannabis
among those diagnosed with psychosis, despite evi-
dence that such use may exacerbate their illness. In
support of this, subjective pleasant experiences in the
early stage of cannabis use predict later risks of canna-
bis dependence (Fergusson et al. 2003) and, further-
more, seem to be inﬂuenced by genetic factors
(Lyons et al. 1997).
In testing any of the above models, cannabis potency
needs to be addressed. In recent years, alongside trad-
itional marijuana (grass) and resin (hash), a new potent
variant (often termed skunk) has become widely avail-
able in many countries. Potter et al. (2009) reported
skunk-type cannabis seized in 2005 in England to
have an average Δ9-tetrahydrocannabinol (Δ9-THC)
content of 12.9% compared with an average 3.6% of
hash-type cannabis, while the UK Home Ofﬁce
(Mwenda et al. 2005) reported a slight increase in the
average content of Δ9-THC for both types: 16.2% in
skunk and 5% in hash. Both potency studies also
reported that cannabidiol levels were almost absent
in high-potency skunk-like cannabis (0.1%).
A second aspect to consider closely is that genetic sus-
ceptibility may also render some individuals more vul-
nerable to cannabis-related psychosis. In particular, as
we and others have shown, carriers of the C allele of
AKT1 rs2494732, which is involved in dopamine signal-
ling, havean increased riskofpsychosisonset after canna-
bis use (van Winkel et al. 2011; Di Forti et al. 2012, 2015).
We set out to compare the self-reported effects of
cannabis between ﬁrst-episode psychosis patients and
matched controls from the general population, and to
take into account the type of cannabis used as well
as frequency of use.
Method
Sample
This study utilized a subsample of the Genetic and
Psychosis (GAP) sample (Di Forti et al. 2009) and
comprised 252 patients who met International
Classiﬁcation of Diseases (ICD)-10 (World Health
Organization, 1992) criteria for a ﬁrst episode of psych-
osis (FEP), and 217 controls, all of whom reported
using cannabis. The patients were aged 18–65 and pre-
sented with a FEP to the Lambeth, Southwark and
Croydon adult in-patient units of the South London
and Maudsley (SLaM) NHS Foundation Trust, be-
tween 1 May 2005 and 31 May 2011. In addition to
ICD-10, the Schedules for Clinical Assessment in
Neurosychiatry (SCAN; Wing et al. 1990) were used
to clarify symptomatology during the month before
the assessment. Patients who met the diagnostic cri-
teria for organic psychosis (ICD-10, F09) were excluded
from the cohort. The control group was recruited from
the same area of South-East London; those who met
criteria for a psychotic disorder or with a previous
diagnosis of psychotic illness were excluded (Di Forti
et al. 2009).
Measures
We collected sociodemographic data (age, gender; self-
reported ethnicity) through the Medical Research
Council Social Schedule (MRCSS). From March 2006,
we collected more detailed history of cannabis use by
adding the Cannabis Experience Questionnaire mod-
iﬁed version (CEQmv; Di Forti et al. 2009); this included
frequency of use and type of cannabis used, age of ﬁrst
use, if they still use, frequency of this current use and
the use of other substances. We investigated experi-
ences reported both during and after cannabis intoxica-
tion, which were collected with a ﬁve-point Likert scale
(from rarely or never to always) and a subjective rating
of the quality of that experience (‘good’, ‘bad’ or ‘neu-
tral’). Contrary to the original version of the CEQ
(Barkus et al. 2006), which included 55 experiences,
the CEQmv (Di Forti et al. 2009) includes only 14
items to reduce respondent burden (which was
selected following factor analyses; Table 2).
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All participants were also asked to describe the type
of cannabis they typically used, and divided into two
categories: hash-type (median THC: 3.54%) and skunk-
type (median THC: 13.98%); according to features of
cannabis samples seized by the Metropolitan Police
in South-East London and the later UK Home Ofﬁce
Study (Hardwick & King, 2008; Potter et al. 2009),
grass-type cannabis is rarely used in this area and
less than 1% of participants used it. In our study
those using imported herbal cannabis were included
in the high-potency category due to the high level of
THC contained (Potter et al. 2009).
Statistical analysis
The χ2 test was used to compare cannabis-related
experiences in patients and controls and Pearson corre-
lations to investigate the relationship between the
experiences, and the frequency, the type of cannabis
use and the genetic vulnerability to psychosis symp-
tomatology. Principal component analysis with
Varimax rotation was run in order to create variables
able to summarize the areas involved in cannabis in-
toxication and understand if these cannabis-related
experiences could have any role in the maintenance
of cannabis use.
The components obtained with the principal compo-
nent analysis were analysed using multiple linear re-
gression to understand the relationship between
experiences and environmental/personal variables.
For each factor a score was calculated using the factor
loadings and this formed the dependent variable in lin-
ear regression analyses. Independent variables
included: the ‘will to stop using cannabis’, the ‘amount
of money spent per week on cannabis’, the ‘duration of
cannabis use’ and the ‘current status (as current user or
not)’, the ‘frequency of cannabis use’, the ‘type of can-
nabis mostly used’, the ‘age at ﬁrst cannabis use’, the
‘presence of positive family history for psychosis or
for other psychiatric disorders’ and the ‘beliefs about
the impact of cannabis use on health’. ‘Caseness’ (pres-
ence of diagnosis of a psychotic disorder) was forced as
an independent variable for all the analyses.
To account for multiple comparisons we used
Bonferroni correction (on the basis of the number of
predictors included) and only p values lower than
0.006 were considered signiﬁcant.
Results
A total of 252 patients [74.6% male; mean age 28 (S.D. =
8.32) years] and 217 controls [57.4% male; mean age 30
(S.D. = 9.49) years] were included in the analysis. Of the
FEP participants, 22.8% were employed at the time of
the interview compared with 61.0% of controls;
18.8% of patients had no education qualiﬁcation as
opposed to 2.5% of the controls. The duration of canna-
bis use did not differ between the two groups.
However, high-potency skunk-like cannabis was
more commonly used by FEP patients (83.7%) than
controls (44.4%) (Table 1).
Cannabis-related experiences
The experiences were divided into two categories: (a)
experiences during cannabis intoxication; and (b)
experiences after the effect of cannabis had worn off.
Both categories showed signiﬁcant differences between
patients and controls (Table 2). For experiences ‘dur-
ing’ cannabis use, feeling like going mad (χ2 = 13.729,
p = 0.001), feeling nervous (χ2 = 12.287, p = 0.002), feel-
ing suspicious without a reason (χ2 = 9.556, p = 0.002),
feeling happy (χ2 = 10.439, p = 0.005), feeling full of
plans (χ2 = 8.544, p = 0.014) and hearing voices (χ2 =
10.644, p = 0.005) were more common within FEP parti-
cipants than controls.
Additionally, some experiences ‘after’ cannabis use
were more frequently noted by patients than controls:
being suspicious without a reason (χ2 = 6.737, p = 0.034)
and difﬁculty concentrating (χ2 = 13.496, p = 0.001).
Principal component analysis
A Principal component analysis with Varimax rotation
of the 13 cannabis experiences (Table 3) identiﬁed four
factors (eigenvalues between 1.183 and 4.575) which
overall explained 62.3% of the total variance in
cannabis-related experiences. Each of the four factors
was retained in subsequent analyses as each explained
more than 10% of the total variance. The factor load-
ings and item-total correlations for this four-factor so-
lution are summarized in Table 3.
The ﬁrst factor component was deﬁned by four
items each with a factor loading >0.5, and explained
21.0% of the total variance. Even though the item
‘how often have you felt suspicious without a reason
after effects of cannabis have worn off?’ showed a
higher factor loading for another component as well,
we considered it part of the this component to preserve
its coherence. This component had good internal con-
sistency (Cronbach’s α = 0.78) and the items showed ac-
ceptable item-total correlations. The items included in
this factor related to anxiety, fear and suspicion and
therefore this factor was labelled as ‘anxiety–paranoid’.
The second factor component consisted of three
items with each factor loading >0.5 and explained
16.09% of the total variance; this component also dis-
played good internal consistency (Cronbach’s α =
0.77) and the items, which form it, showed good item-
total correlation. The items comprising this factor
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related to thought and concentration and we therefore
labelled this factor ‘cognitive experiences’.
The third factor component, which we called ‘enjoy-
able experiences’ due to all the pleasant experiences
included, showed acceptable Cronbach’s α values
(0.63) and item-total correlations. This component
explained 13.1% of the total variance.
The ﬁnal factor component was characterized by the
presence of positive symptoms and we labelled it
‘psychotic experiences’. This explained 12.2% of the
total variance, had a lower internal consistency index
(Cronbach’s α = 0.58) but its items displayed an accept-
able level of item-total correlation.
Linear regression
The best-ﬁtting models (Table 4) showed that belief
about the impact of cannabis on health was one of
the strongest predictors of unpleasant experiences,
suggesting that cannabis users are able to identify ad-
verse effects of cannabis. However, awareness of the
adverse effects of cannabis was not associated with a
stronger motivation to stop using cannabis. Investigat-
ing the whole-sample ‘enjoyable experiences’ did not
show any strong association with the considered inde-
pendent variables; considering only the FEP subgroup,
this factor was positively related to the amount of
money spent weekly on cannabis as well as to a longer
duration of cannabis use (Table 5), suggesting that
these positive experiences reinforce further cannabis
use in psychotic patients.
Use of high-potency cannabis was related to more fre-
quent psychotic experiences, indicating that use of skunk
instead of hash increased psychotic symptomatology.
To better understand the relationship between psych-
otic illnesses and sensitivity to the effects of cannabis,
we tested for signiﬁcant interactions between caseness
and each of the signiﬁcant predictors. None of these
interactions was signiﬁcant, suggesting that the associa-
tions between predictors and cannabis-related experi-
ences did not differ between patients and controls.
No multillinearity problems were found between the
considered predictors.
Discussion
In line with our previous reports, the FEP subjects in our
sample, relative to controls, were more likely to use can-
nabis frequently, preferred potent varieties (Di Forti
et al. 2009, 2015; Kolliakou et al. 2011) and reported an
earlier age of onset of cannabis use (Di Forti et al.
2014). Although there were no signiﬁcant differences
in the duration of cannabis use between the two groups,
at the time of the interviews, more patients than controls
had been currently smoking cannabis.
We show that FEP patients showed higher sensitiv-
ity to cannabis than controls as also reported in other
studies (Radhakrishnan et al. 2014). This hypersensi-
tiveness involved not only more frequent ‘unpleasant
experiences’ but also increased ‘enjoyable feelings’.
These intensiﬁed enjoyable experiences could re-
inforce, working as a reward, cannabis use (Wetherill
et al. 2014) in both patients and controls, increasing
the risk of developing cannabis dependence and balan-
cing, at the same time, the experience of unpleasant
effects.
Table 1. Sociodemographic characteristics and patterns of cannabis
use in cases and controls
Cases
(n = 252)
Controls
(n = 217) χ2 (df)
Mean age, years (S.D.) 28 (8.32) 30 (9.49)
Gender, n (%) <0.001 (1)
Male 188 (74.6) 124 (57.4)
Female 64 (25.4) 92 (42.6)
Ethnicity, n (%) <0.001(3)
White 102 (40.5) 144 (67.9)
Black Caribbean 41 (16.3) 27 (12.7)
Black African 45 (17.9) 14 (6.6)
Other 64 (25.4) 27 (12.7)
Employment, n (%) <0.001 (2)
Employed 43 (22.8) 94 (61.0)
Student 16 (8.5) 36 (23.4)
Unemployed 130 (68.8) 24 (15.6)
Education, n (%) <0.001 (1)
No qualiﬁcation 36 (18.8) 4 (2.5)
Any qualiﬁcation 155 (81.2) 153 (97.5)
Mean age of ﬁrst
cannabis use,
years (S.D.)
16 (4.77) 17 (3.33)
Mean duration of
cannabis use,
years (S.D.)
9.63 (9.13) 9.62 (8.89)
Type of cannabis
used, n (%)
<0.001 (1)
Skunk type 159 (83.7) 63 (44.4)
Hash type 31 (16.3) 79 (55.6)
Other drugs lifetime
use, n (%)
>0.05 (1)
No 88 (40.0) 82 (44.6)
Yes 132 (60.0) 102 (55.4)
Tobacco lifetime
use, n (%)
<0.001 (1)
No 18 (8.1) 71 (34.8)
Yes 205 (91.9) 133 (65.2)
Alcohol use, n (%) >0.05 (1)
<14 units per week 67 (65.0) 111 (68.9)
>14 units per week 36 (35.0) 50 (31.1)
df, Degrees of freedom; S.D., standard deviation.
4 F. Bianconi et al.
Table 2. Cannabis experiences in patients v. controls
Patients, n (%)
(n = 252)
Controls,
n (%) (n = 217) χ2 p (df = 2)
How often have you felt fearful
while smoking cannabis?
Rarely or never 125 (65.4) 86 (66.2)
From time to time 15 (7.9) 16 (12.3) 2.433 0.296
Sometimes, more often than not,
almost always
51 (26.7) 28 (21.5)
How often have you felt mad
while smoking cannabis?
Rarely or never 134 (70.2) 107 (82.3)
From time to time 9 (4.7) 11 (8.5) 13.729 0.001
Sometimes, more often than not,
almost always
48 (25.1) 12 (9.2)
How often have you felt nervy
while smoking cannabis?
Rarely or never 102 (53.7) 80 (61.5)
From time to time 20 (10.5) 25 (19.2) 12.278 0.002
Sometimes, more often than not,
almost always
68 (35.8) 25 (19.2)
How often have you felt
suspicious while smoking
cannabis?
Rarely or never 100 (53.2) 70 (53.8)
From time to time 14 (7.4) 23 (17.7) 9.556 0.008
Sometimes, more often than not,
almost always
74 (39.4) 37 (28.5)
How often have you felt happy
while smoking cannabis?
Rarely or never 37 (19.3) 17 (13.1)
From time to time 11 (5.7) 21 (16.2) 10.439 0.005
Sometimes, more often than not,
almost always
144 (75.0) 92 (70.8)
How often have you felt full of
plans while smoking cannabis?
Rarely or never 66 (35.1) 58 (45.0)
From time to time 16 (8.5) 19 (14.7) 8.544 0.014
Sometimes, more often than not,
almost always
106 (56.4) 52 (40.3)
How often have you heard voices
while smoking cannabis?
Rarely or never 143 (75.7) 116 (89.9)
From time to time 10 (5.3) 4 (3.1) 10.644 0.005
Sometimes, more often than not,
almost always
36 (19.0) 9 (7.0)
How often have you felt able to
understand the world better
while smoking cannabis?
Rarely or never 93 (49.7) 71 (54.6)
From time to time 11 (5.9) 15 (11.5) 5.471 0.065
Sometimes, more often than not,
almost always
83 (44.4) 44 (33.8)
How often have you had visions
while smoking cannabis?
Rarely or never 161 (85.2) 112 (86.8)
From time to time 10 (5.3) 3 (2.3) 1.808 0.405
Sometimes, more often than not,
almost always
18 (9.5) 14 (10.9)
How often have you felt not
wanting to do anything after
effects of cannabis haveworn off?
Rarely or never 78 (43.6) 45 (40.5)
From time to time 13 (7.3) 12 (10.8) 1.153 0.562
Sometimes, more often than not,
almost always
88 (49.2) 54 (48.6)
How often have you felt
suspicious without a reason after
effects of cannabis haveworn off?
Rarely or never 109 (61.2) 82 (74.5)
From time to time 14 (7.9) 9 (8.2) 6.737 0.034
Sometimes, more often than not,
almost always
55 (30.9) 19 (17.3)
How often have you felt your
thinking was slowed down after
effects of cannabis haveworn off?
Rarely or never 92 (51.7) 51 (45.9)
From time to time 14 (7.9) 19 (17.1) 5.796 0.055
Sometimes, more often than not,
almost always
72 (40.4) 41 (36.9)
How often have you had difﬁculty
concentrating after effects of
cannabis have worn off?
Rarely or never 86 (48.6) 52 (46.8)
From time to time 12 (6.8) 23 (20.7) 13.496 0.001
Sometimes, more often than not,
almost always
79 (44.6) 36 (32.4)
df, Degrees of freedom.
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Table 3. Principal component analysis of cannabis-related experiences
Factor 1 ‘anxiety–paranoid
experiences’
Factor 2 ‘cognitive
experiences’
Factor 3 ‘enjoyable
experiences’
Factor 4 ‘psychotic
experiences’
Factor
loading
Item-total
correlation
Factor
loading
Item-total
correlation
Factor
loading
Item-total
correlation
Factor
loading
Item-total
correlation
How often have you felt suspicious while smoking
cannabis?
0.776 0.574
How often have you felt nervy while smoking cannabis? 0.760 0.567
How often have you felt fearful while smoking cannabis 0.701 0.558
How often have you felt suspicious without a reason after
effects of cannabis have worn off?
0.591 0.554
How often have you felt your thinking was slowed down
after effects of cannabis have worn off?
0.796 0.624
How often have you had difﬁculty concentrating after
effects of cannabis have worn off?
0.787 0.615
How often have you felt not wanting to do anything after
effects of cannabis have worn off?
0.717 0.559
How often have you felt able to understand the world
better while smoking cannabis?
0.741 0.424
How often have you felt full of plans while smoking
cannabis?
0.730 0.510
How often have you felt happy while smoking cannabis? 0.705 0.388
How often have you had visions while smoking
cannabis?
0.765 0.355
How often have you heard voices while smoking
cannabis?
0.677 0.472
How often have you felt like going mad while smoking
cannabis?
0.588 0.522
% Variance explained 21.0 16.1 13.1 12.2
Cronbach’s α 0.78 0.77 0.63 0.58
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We found that a larger amount of money spent per
week was positively associated with enjoyable experi-
ences in the patient group whereas unpleasant experi-
ences were positively associated with the presence of
beliefs about the impact of cannabis use on health;
thus, FEP patients were aware of the unhealthy effect
of cannabis on them.
We demonstrate that psychotic patients are more
susceptible to all the psychological effects of cannabis,
not only the positive ones as shown in previous litera-
ture (Thornton et al. 2012). Happiness and ﬂuency of
thinking were more often reported by patients than
controls and were positively associated with a larger
amount of money spent per week to purchase the sub-
stance. It is likely that these positive cannabis-related
experiences may contribute to the persistence of canna-
bis use in psychotic patients, consistent with previous
ﬁndings (Zeiger et al. 2012).
The signiﬁcant association between more frequent
cannabis-related psychotic experiences and the potent
variant of cannabis is in line with the association be-
tween the use of skunk and higher risk of psychosis
which we previously found (Di Forti et al. 2015).
Why are psychotic patients more sensitive to canna-
bis? One possibility is that they become more sensi-
tive following the onset of psychosis. An alternative
explanation is that they already held an intrinsic sen-
sitivity. For instance, evidence has suggested a role of
variation in the AKT1 gene in inﬂuencing the individ-
ual response to the psychotogenic properties of can-
nabis use (van Winkel et al. 2011; Di Forti et al.
2012, 2015). The AKT1 gene encodes for a kinase
protein involved in post-synaptic D2 dopamine sig-
nalling and to post-synaptic sensitivity and it has
been suggested to moderate the risk for psychosis
(Murray et al. 2014).
These results should be considered in the light of
some limitations and strengths; ﬁrst of all the large
number of missing data; 61.4% of our sample com-
pleted all questions about the experiences included in
the CEQ with a range of missing data between 31.3
and 38.6%; as reported earlier a large proportion of
those missing data was related to the later introduction
of the CEQmv in the collection of cannabis history; a
higher presence of missing data was also observed
within the control group, especially for those who
had used cannabis once.
In conclusion, our ﬁndings highlight the hypersensi-
tiveness of FEP patients to the effects of cannabis; this
hypersensitiveness was linked to stronger experiences
not only during intoxication, but also to cognitive im-
pairment after cannabis use and these, as well as
other experiences, were also related to genetic suscep-
tibility. Contrary to the self-medication hypothesis,
cannabis did not relieve psychotic symptomatology
as higher levels of psychotic experiences were reported
by FEP patients. It seems that other factors, including
pleasure seeking, may encourage and maintain canna-
bis use in FEP patients. The relationship between the
type of cannabis use and a massive presence of psych-
otic experiences support the causal model, highlighting
the presence of a third factor which increases the risk to
have psychotic-related experiences after cannabis use.
Our ﬁndings concerning both skunk use and more
enjoyable experiences reported during cannabis intoxi-
cation are in line with the indicator variable model
showing how different factors can guide the relation-
ship between psychosis-proneness and cannabis use.
Table 4. Linear regression analysis aspects of cannabis use and belief about the health effects of cannabis on subjective experiences of cannabis
usea
Anxiety–paranoid
experiences
Cognitive
experiences Psychotic experiences
Enjoyable
experiences
B p B p B p B p
Caseness −0.042 (0.24) 0.86 −0.35 (0.31) 0.26 0.23 (0.16) 0.143 −0.07 (0.174) 0.69
Type of cannabis used 1.03 (0.34) <0.01**
Belief about the effect of
cannabis on health
2.11 (0.38) <0.001*** 1.52 (0.49) <0.01** 0.96 (0.27) <0.001***
R2 0.421 0.183 0.264
p <0.001*** <0.01** <0.001***
Data are given as regression coefﬁcient (standard error).
a Predictors which did not show signiﬁcant results with the dependent variables are not reported in this table: alcohol use;
other drugs use; tobacco use; amount of money spent on cannabis; duration of cannabis use; frequency of cannabis use.
Confounder variables: age, gender and ethnicity.
** p <0.01, *** p <0.001.
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Because our data were collected from a FEP popula-
tion and the cannabis-related experiences included
experiences occurring both before and after the onset
of psychosis, further prospective studies should assess
the changes in subjective cannabis experiences before
and after the exacerbation of psychosis considering
also if antipsychotic medication could change the sub-
jective cannabis-related experience playing a role in
the maintenance of cannabis use. The role of individual
genetic variants and/or polygenic risk score for psych-
osis should be explored to understand their role in
inﬂuencing the quality and frequency of cannabis-
related experience and the maintenance of cannabis use.
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